Avid Bioservices, Inc. (CDMO)
CDMO Price and Sentiment
CDMO Latest news
The stock will be part of a well-known index.
Soaring Eagle Acquisition is about to complete its merger with Ginkgo Bioworks, and SRNG stock is reacting well. Here's why.
Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q2 2021 Results - Earnings Call Transcript
Healthcare is one market no one can say is going to slow down, and so, many of the best investments lie within.
Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry Experience Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry Experience
Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q4 2021 Results - Earnings Call Transcript
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments2021-06-29 16:05
-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 --
Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 20212021-06-22 16:05
TUSTIN, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year (FY) ended April 30, 2021 on June 29, 2021 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the quarter and FY ended April 30, 2021 and review recent corporate developments.
Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.